These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31535305)

  • 41. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer.
    Carlson JJ; Guzauskas GF; Dann RA; Ramsey SD
    J Med Econ; 2021; 24(1):1309-1317. PubMed ID: 34763605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review.
    Tan J; Wang Y; Liu S; Shi Q; Zhou X; Zhou Y; Yang X; Chen P; Li S
    Front Pharmacol; 2021; 12():669814. PubMed ID: 34079464
    [No Abstract]   [Full Text] [Related]  

  • 44. Adherence and Swallowing Experience with a Modified, Smaller-sized Tablet Formulation of Metformin and Glimepiride (SR) in Indian Patients with Type 2 Diabetes Mellitus.
    Modi KD; Farishta F; Phatak S; Godbole SG; Banzal S
    J Assoc Physicians India; 2019 Dec; 67(12):44-49. PubMed ID: 31801331
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
    J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.
    Gu S; Zeng Y; Yu D; Hu X; Dong H
    PLoS One; 2016; 11(11):e0167190. PubMed ID: 27875596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial.
    Saunders R; Lian J; Karolicki B; Valentine W
    J Med Econ; 2014 Dec; 17(12):827-36. PubMed ID: 25168164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advantages of extended-release metformin in patients with type 2 diabetes mellitus.
    Jabbour S; Ziring B
    Postgrad Med; 2011 Jan; 123(1):15-23. PubMed ID: 21293080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.
    Biskupiak JE; Ramos M; Levy CJ; Forlenza G; Hopley C; Boyd J; Swift D; Lamotte M; Brixner DI
    J Manag Care Spec Pharm; 2023 Jul; 29(7):807-817. PubMed ID: 37133431
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A; Rastogi M; Dhankhar P; Bell KF
    J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program.
    Molteni L; Marelli G; Castagna G; Brambilla L; Acerbis M; Alberghina F; Carpani A; Chiavenna E; Ferlini MG; Impellizzeri C; Paredi R; Rigamonti A; Rivolta G; Disoteo OE
    Endocr Metab Immune Disord Drug Targets; 2024; 24(12):1422-1430. PubMed ID: 38425116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans.
    Phelps H; Lin D; Keenan A; Raju A; Huang D; Cheng CY; Benson C
    J Manag Care Spec Pharm; 2023 Mar; 29(3):303-313. PubMed ID: 36840957
    [No Abstract]   [Full Text] [Related]  

  • 56. Fixed-dose combination therapy in type 2 diabetes mellitus.
    Blonde L; San Juan ZT; Bolton P
    Endocr Pract; 2014 Dec; 20(12):1322-32. PubMed ID: 25370323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.
    Al-Omar HA; Almodaimegh HS; Omaer A; Alzubaidi LM; Al-Harbi B; Al-Harbi I; Hassan M; Akhtar O
    J Med Econ; 2024; 27(1):418-429. PubMed ID: 38420695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Budget impact of lasmiditan for the acute treatment of migraine in the United States.
    Milev S; Pohl G; Sun A; Mason O; Njuguna N; Loo LS
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1714-1723. PubMed ID: 34818093
    [No Abstract]   [Full Text] [Related]  

  • 59. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
    Van der Linden N; Van Olst S; Nekeman S; Uyl-de Groot CA
    Diabet Med; 2021 Apr; 38(4):e14371. PubMed ID: 32745279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.